Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[5-fluorouracil].

K Aiba1

  • 1Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 1-37-1 Kamiikebukuro, Toshima-ku, Tokyo 170-8455, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 30, 2001
PubMed
Summary

For decades, optimal dosing for 5-fluorouracil (5-FU) remains elusive. New oral 5-FU derivatives may soon replace protracted infusion, offering improved therapeutic outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial.

ESMO open·2021
Same author

The analysis of the innate pathways of 5-fluorouracil phosphorylation in human gastrointestinal cancer cell lines in vitro and in vivo.

Oncology reports·2011
Same author

Pilot study of continuous low-dose 5-fluorouracil and cisplatin (FP regimen) for the treatment of metastatic breast cancer.

International journal of clinical oncology·2010
Same author

Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels.

Endocrine-related cancer·2003
Same author

Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline.

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same author

[Comparison of management of advanced cancer in various organs].

Gan to kagaku ryoho. Cancer & chemotherapy·2001

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Therapeutics

Context:

  • 5-fluorouracil (5-FU) has been investigated for decades to optimize cancer treatment.
  • No universally accepted standard dose or schedule for 5-FU has been established.
  • 5-FU exhibits dual mechanisms of cytotoxicity, affecting both DNA and RNA.

Purpose:

  • To review the optimal dosing and scheduling of 5-FU for improved therapeutic ratios.
  • To explore strategies for maximizing efficacy and minimizing toxicity of 5-FU.
  • To evaluate the potential of new oral 5-FU derivatives in cancer therapy.

Summary:

  • Despite extensive research, optimal 5-FU dosing and scheduling remain undetermined.
  • Protracted infusion (PI) is currently considered an effective method for 5-FU administration.
  • Emerging oral 5-FU derivatives with similar pharmacological profiles to PI are expected to become standard.

Impact:

  • This review highlights the ongoing challenges in 5-FU therapy optimization.
  • It suggests a shift towards more convenient and potentially more effective oral formulations.
  • The findings may guide future clinical practice and drug development in 5-FU-based chemotherapy.

Related Experiment Videos